Immunotherapies involving the PD-1 / PD-L1 axis have revolutionized the treatment of non-small cell lung cancer (NSCLC), but novel combination therapies are needed to improve the overall response rate. The gene discussed is CD274; the disease is non-small cell lung carcinoma.